Last reviewed · How we verify
Interferon Alfa、Fluorouracil
Interferon alfa binds to interferon receptors on the surface of cells, leading to the activation of JAK-STAT signaling pathways which enhance antiviral and antiproliferative responses; Fluorouracil inhibits thymidylate synthase, disrupting DNA synthesis and repair in rapidly dividing cells.
Interferon alfa binds to interferon receptors on the surface of cells, leading to the activation of JAK-STAT signaling pathways which enhance antiviral and antiproliferative responses; Fluorouracil inhibits thymidylate synthase, disrupting DNA synthesis and repair in rapidly dividing cells. Used for Hepatocellular carcinoma.
At a glance
| Generic name | Interferon Alfa、Fluorouracil |
|---|---|
| Also known as | Interferon Alfa ; IFN、, Fluorouracil ; 5-FU |
| Sponsor | Kansai Hepatobiliary Oncology Group |
| Drug class | Interferon alfa: cytokine; Fluorouracil: antimetabolite |
| Target | Interferon alfa: IFNAR1/IFNAR2; Fluorouracil: thymidylate synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Interferon alfa activates the JAK-STAT pathway, which increases the expression of genes involved in antiviral defense and immune modulation. Fluorouracil's inhibition of thymidylate synthase leads to a depletion of thymidine triphosphate, essential for DNA replication, thereby inducing apoptosis in cancer cells.
Approved indications
- Hepatocellular carcinoma
Common side effects
- Fatigue
- Nausea
- Neutropenia
Key clinical trials
- Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer (PHASE1, PHASE2)
- Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer (PHASE2)
- P2 Study of Postoperative Interferon/Fluorouracil vs Cisplatin/Fluorouracil for Hepatocellular Carcinoma. (PHASE2)
- Chemoradiation in Locally Advanced Pancreatic Cancer (PHASE2)
- Adjuvant Chemoradiotherapy and Interferon Alfa in Treating Patients With Resected Pancreatic Cancer (PHASE2)
- Recombinant Anti-tumor and Anti-virus Protein for Injection Plus Xeloda in Treatment of Metastatic Colorectal Cancer (PHASE2)
- A Phase II Study of a Continuous Hepatic Arterial Infusion Combination Therapy With OPC-18 and 5-FU in Patients With Highly Advanced Hepatocellular Carcinoma (PHASE2)
- Interferon Alfa With or Without Interleukin-2 and Fluorouracil in Treating Patients With Advanced Metastatic Kidney Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |